Lipid Nanoparticle– tag –
-
2026 ‘In Vivo CRISPR Medicine’ Symposium to Focus on Commercialization and Scalable Deployment of In Vivo Genome Editing
CRISPR Medicine News (CMN x CSGCT Virtual Symposium) USA Overview The upcoming 'In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale' virtual symposium on September 3, 2026, will highlight the transition of in vivo genom... -
ReCode Therapeutics Secures Funding, Partners with Gene Editing Firm to Fast-Track Cystic Fibrosis Gene Therapy with SORT LNP Platform
BioSpace (via Business Wire) USA Overview ReCode Therapeutics has announced new funding from the Cystic Fibrosis Foundation and a strategic partnership with a leading gene editing company. These initiatives will accelerate the developmen... -
Peking University Unveils SynTar LNPs: A Precision Breakthrough for Targeted mRNA Lung Delivery
SINOPEG China Overview Researchers at Peking University have developed an innovative SynTar lipid nanoparticle (SynTar LNP) platform, overcoming a critical bottleneck in targeted mRNA delivery to the lungs. This system significantly enha... -
AI-Powered In Silico Design Revolutionizes RNA-LNP Therapies for Targeted Delivery and CRISPR Gene Editing
InSilicoMinds USA Overview In silico (computational) design is fundamentally transforming the development of lipid nanoparticle (LNP) and RNA therapeutics by enabling the precise optimization of LNP properties for tissue-specific drug de... -
Nanoparticle Breakthroughs: Piercing the Blood-Brain Barrier to Revolutionize CNS Disease Treatment, Including Glioblastoma
MDPI Switzerland Overview Nanoparticle-based drug delivery systems are emerging as a pivotal solution for overcoming the blood-brain barrier (BBB), a critical challenge in treating central nervous system (CNS) diseases. A recent review h... -
Unlocking mRNA LNP Design: Cholesterol Found Unnecessary for Non-Hepatic Delivery
ACS Nano USA Overview New research thoroughly dissects the functional roles of individual lipid components within mRNA lipid nanoparticles (LNPs), revealing that while ionizable lipids are critical for delivery efficacy, cholesterol is e... -
Comprehensive Guide Published: RNA Therapeutics, from ASO to LNP/GalNAc Platforms, Shaping the Future of Precision Medicine
MDPI International Overview A comprehensive guide published by MDPI overviews the engineering history of RNA therapeutics, spanning from ASOs to modern siRNA and mRNA-LNP-based therapies. It highlights a growing regulatory trend favoring... -
Dual-Targeting Lipid Nanoparticles Drastically Enhance β Cell-Specific RNA Delivery, Promising for Type 1 Diabetes Therapy
ACS Publications USA Overview Researchers have developed a dual-targeting lipid nanoparticle (LNP) engineering strategy that significantly enhances β cell-directed RNA delivery. This novel LNP demonstrated substantially improved in vivo ... -
SyVento Biotech and Biotechna Forge Alliance to Advance siRNA/LNP Cancer Therapeutics into Clinical Trials
SyVento Biotech Poland Overview SyVento Biotech and Biotechna have announced a strategic partnership to co-develop siRNA/LNP-based anti-cancer therapeutics, targeting solid tumors like lung and breast cancer through precise nucleic acid ... -
AGC Biologics Secures Multi-Million Dollar Manufacturing Deal for Yokohama Facility, Boosting LNP Production Capacity
히트뉴스 Japan Overview AGC Biologics, a global CDMO, has secured a multi-year commercial manufacturing contract, valued at hundreds of millions of dollars, for its new Yokohama facility in Japan, slated to open in 2027. An undisclosed b...
